| 2024-10 |
Enhanced production of recombinant coxsackievirus A16 using a serum-free HEK293A suspension culture system for bivalent enterovirus vaccine development |
Vaccine: X. 2024 Oct;20:Article number 100559. |
 |
| 2023-12 |
The stability and immunogenicity of formalin-inactivated Enterovirus A71 whole virion vaccine after ten years of low temperature storage |
Journal of Microbiology, Immunology and Infection. 2023 Dec;56(6):1121-1128. |
|
| 2023-03-24 |
Propagation and immunological characterization of coxsackievirus A10 in a serum-free HEK293A cell culture system |
Virus Research. 2023 Mar 24;329:Article number 199101. |
|
| 2022-09-15 |
The uncoating of EV71 in mature late endosomes requires CD-M6PR |
Biology Open. 2022 Sep 15;11(9):Article number bio059469. |
|
| 2022-09-13 |
Separation and purification of highly infectious enterovirus A71 particles using a strong anion-exchange column |
Journal of Chromatography A. 2022 Sep 13;1680:Article number 463427. |
|
| 2022-05-08 |
Intranasal immunization with zika virus envelope domain III-flagellin fusion protein elicits systemic and mucosal immune responses and protection against subcutaneous and intravaginal virus challenges |
Pharmaceutics. 2022 May 8;14(5):Article number 1014. |
|
| 2022-01 |
Novel strategies for the development of hand, foot, and mouth disease vaccines and antiviral therapies |
Expert Opinion on Drug Discovery. 2022 Jan;17(1):27-39. |
|
| 2021-11-14 |
Production of multi-subtype influenza virus-like particles by molecular fusion with BAFF or APRIL for vaccine development |
Methods in Molecular Biology. 2021 Nov 14;2248:139-153. |
|
| 2021-01-26 |
作为对抗肠病毒感染之免疫原的病毒颗粒及其制造 |
CN106661102B/2021-01-26 |
|
| 2020-10-21 |
エンテロウイルス感染に対する免疫原としてのウイルス粒子およびその生産(Viral particles and their production as immunogens against enterovirus infection) |
JP6774149B2/2020-10-21 |
|
| 2020-03-02 |
作為對抗腸病毒感染之免疫原的病毒顆粒及其製造 |
I688652/2020-03-02 |
|
| 2019-11 |
Recombinant hemagglutinin produced from Chinese Hamster Ovary (CHO) stable cell clones and a PELC/CpG combination adjuvant for H7N9 subunit vaccine development |
Vaccine. 2019 Nov;37(47):6933-6941. |
|
| 2019-04 |
Highly immunogenic influenza virus-like particles containing B-cell-activating factor (BAFF) for multi-subtype vaccine development |
Antiviral Research. 2019 Apr;164:12-22. |
|
| 2019-03 |
Glycan-masking hemagglutinin antigens from stable CHO cell clones for H5N1 avian influenza vaccine development |
Biotechnology and Bioengineering. 2019 Mar;116(3):598-609. |
|
| 2018-08-22 |
Recent development of enterovirus a vaccine candidates for the prevention of hand, foot, and mouth disease |
Expert Review of Vaccines. 2018 Aug 22;17(9):819-831. |
|
| 2018-08 |
Maternal immunization with a recombinant adenovirus-expressing fusion protein protects neonatal cotton rats from respiratory syncytia virus infection by transferring antibodies via breast milk and placenta |
Virology. 2018 Aug;521:181-189. |
|
| 2018-06-04 |
Mutations in VP1 and 5′-UTR affect enterovirus 71 virulence [Erratum: Scientific Reports. 2018 Apr 27;8(1):Article number 6688.] |
Scientific Reports. 2018 Jun 4;8:Article number 8744. |
|
| 2018-05 |
Enhancing enterovirus A71 vaccine production yield by microcarrier profusion bioreactor culture |
Vaccine. 2018 May;36(22):3134-3139. |
|
| 2018-04-27 |
Mutations in VP1 and 5′-UTR affect enterovirus 71 virulence |
Scientific Reports. 2018 Apr 27;8(1):Article number 6688. |
|
| 2016-09 |
Multi-subtype influenza virus-like particles incorporated with flagellin and granulocyte-macrophage colony-stimulating factor for vaccine design |
Antiviral Research. 2016 Sep;133:110-118. |
|
| 2016-08 |
Development of a full-length cDNA-derived enterovirus A71 vaccine candidate using reverse genetics technology |
Antiviral Research. 2016 Aug;132:225-232. |
|
| 2016-06 |
Immunogenicity of an adeno-vector vaccine expressing the F protein of a respiratory syncytial virus manufactured from serum-free suspension culture |
Antiviral Research. 2016 Jun;130:27-35. |
|
| 2016-05 |
Immunological and biochemical characterizations of Coxsackievirus A6 and A10 viral particles |
Antiviral Research. 2016 May;129:58-66. |
|
| 2015-11-18 |
对抗肠病毒71型的单源抗体及其用途 |
ZL201110154504.5/2015-11-18 |
|
| 2015-06-11 |
對抗腸病毒７１型之單株抗體及其用途 |
I487537/2015-06-11 |
|
| 2015-06-09 |
Immunogenic compositions and uses thereof |
US9051361B2/2015-06-09 |
|
| 2015-04-21 |
免疫原性組合物及其用途 |
I481717/2015-04-21 |
|
| 2015-04 |
Recombinant adeno-vaccine expressing Enterovirus 71-like particles against hand, foot, and mouth disease |
PLoS Neglected Tropical Diseases. 2015 Apr;9(4):Article number e0003692. |
|
| 2015-03 |
Review of enterovirus 71 vaccines |
Clinical Infectious Diseases. 2015 Mar;60(5):797-803. |
|
| 2014-10 |
Prospect and challenges for the development of multivalent vaccines against hand, foot and mouth diseases |
Vaccine. 2014 Oct;32(47):6177-6182. |
|
| 2014-09-08 |
Long-term immunogenicity studies of formalin-inactivated Enterovirus 71 whole-virion vaccine in macaques |
PLoS ONE. 2014 Sep 8;9(9):Article number e106756. |
|
| 2014-08-27 |
Delivery of human EV71 receptors by adeno-associated virus increases EV71 infection-induced local inflammation in adult mice |
BioMed Research International. 2014 Aug 27;2014:Article number 878139. |
|
| 2014-07-30 |
Toll-like receptor 9-mediated protection of enterovirus 71 infection in mice is due to the release of danger-associated molecular patterns |
Journal of Virology. 2014 Jul 30;88(20):11658-11670. |
|
| 2014-06-11 |
Immunogenicity studies of bivalent Inactivated virions of EV71/CVA16 formulated with submicron emulsion systems |
Biomed Research International. 2014 Jun 11;2014:Article number 670506. |
|
| 2013-12 |
Monoclonal antibodies for diagnosis of enterovirus 71 |
Monoclonal Antibodies in Immunodiagnosis and Immunotherapy. 2013 Dec;32(6):386-394. |
|
| 2013-11-21 |
Formalin-inactivated EV71 vaccine candidate induced cross-neutralizing antibody against subgenotypes B1, B4, B5 and C4A in adult volunteers |
PLoS ONE. 2013 Nov 21;8(11):Article number e79783. |
|
| 2013-11 |
Formulation and immunological evaluation of a trivalent vaccine comprising emulsified submicron particles and inactivated virions of H5N1/EV71/JEV |
Human Vaccines and Immunotherapeutics. 2013 Nov ;9(11):2378-2385. |
|
| 2013-10-02 |
Heat Shock protein 90: Role in enterovirus 71 entry and assembly and potential target for therapy |
PLoS ONE. 2013 Oct 2;8(10):Article number e77133. |
|
| 2013-08 |
Caveolar endocytosis is required for human PSGL-1-mediated enterovirus 71 infection |
Journal of Virology. 2013 Aug;7(16):9064-9076. |
|
| 2013-07-30 |
Protective efficacy of VP1-specific neutralizing antibody associated with a reduction of viral load and pro-inflammatory cytokines in human SCARB2-transgenic mice |
PLoS ONE. 2013 Jul 30;8(7):Article number e69858. |
|
| 2013-05 |
A Phase I, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine |
Vaccine. 2013 May;31(20):2471-2476. |
|
| 2013-02-25 |
Human SCARB2 transgenic mice as an infectious animal model for Enterovirus 71 |
PLoS ONE. 2013 Feb 25;8(2):Article number e57591. |
|
| 2012-12 |
Production of EV71 vaccine candidates |
Human Vaccine Immunotherapy. 2012 Dec;8(12):1775-1783. |
|
| 2012-11-30 |
Immunological and biochemical characterization of Coxsackie Virus A16 viral particles |
PLoS ONE. 2012 Nov 30;7(11):Article number e49973. |
|
| 2012-09 |
Immunological evaluation and comparison of different EV71 vaccine candidates |
Clinical and Developmental Immunology. 2012 Sep;2012:Article ID 831282. |
|
| 2012-04 |
Pilot scale production of highly efficacious and stable enterovirus 71 vaccine candidates |
PLoS ONE. 2012 Apr;7(4):Article number e34834. |
|
| 2012-01 |
Selection and characterization of vaccine strain for Enterovirus 71 vaccine development |
Vaccine. 2012 Jan;30(4):703-711. |
|
| 2012-01 |
Human SCARB2-Mediated entry and endocytosis of EV71 |
PLoS ONE. 2012 Jan;7(1):Article number e30507. |
|
| 2011-09 |
Development of a quantitative enzyme linked immunosorbent assay for monitoring the Enterovirus 71 vaccine manufacturing process |
Journal of Virological Methods. 2011 Sep;176(1-2):60-68. |
|
| 2011-06 |
Identification and characterization of a cross-neutralization epitope of Enterovirus 71 |
Vaccine. 2011 Jun;29(26):4362-4372. |
|
